Literature DB >> 10490721

Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children.

S Müller1, A Schulz, U Reiss, K Schwarz, T Schreiner, M Wiesneth, K M Debatin, W Friedrich.   

Abstract

The aim of this study was to reduce the rate of graft failure after HLA non-identical stem cell transplantation by using G-CSF mobilized CD34+ peripheral blood progenitor cells (PBPC), either in combination with bone marrow or as single grafts. To prevent GVHD, PBPC were highly purified, resulting in a 5 to 6 log T cell depletion. In additon to T cell depletion no further GVHD prophylaxis was used. We transplanted 23 pediatric patients with life-threatening malignant or non-malignant hematological disorders, who had no available matched donor. Engraftment was obtained in 18 of 21 evaluable patients. Five patients developed acute GVHD of grade II and III, which became chronic in four cases and was fatal in four. The use of highly purified PBPC allowed the exact quantification of residual T cells in the grafts and a strict correlation between the residual T cell load and the development of GVHD was observed: patients with GVHD had received numbers of T cells between 8 and 20 x 104/kg, whereas patients without GVHD were grafted with T cell numbers ranging from 0.7 to 6.0 x 104/kg. We therefore clearly demonstrate that a residual T cell content of <5 x 104/kg is safe for prevention of GVHD after HLA non-identical PBPC transplantation in children.

Entities:  

Mesh:

Year:  1999        PMID: 10490721     DOI: 10.1038/sj.bmt.1701970

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution.

Authors:  Shelly M Williams; Darin Sumstad; Diane Kadidlo; Julie Curtsinger; Xianghua Luo; Jeffrey S Miller; David H McKenna
Journal:  Transfusion       Date:  2018-03-12       Impact factor: 3.157

2.  Gene Transduction of Natural Killer Cells for Clinical Application.

Authors:  Noriko Shimasaki
Journal:  Methods Mol Biol       Date:  2022

3.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Raul C Ribeiro; Stanley Pounds; Barbara Rooney; Teresa Bell; Ching-Hon Pui; Wing Leung
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

Review 4.  Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases.

Authors:  Franco Aversa; Massimo F Martelli
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

5.  Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.

Authors:  Jeff K Davies; John G Gribben; Lisa L Brennan; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

6.  Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT.

Authors:  J A Park; K N Koh; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo; H J Im
Journal:  Bone Marrow Transplant       Date:  2013-10-21       Impact factor: 5.483

7.  T-cell reconstitution without T-cell immunopathology in two models of T-cell-mediated tissue destruction.

Authors:  Pablo Penaloza-MacMaster; David Masopust; Rafi Ahmed
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

Review 8.  Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells.

Authors:  Jean-François Rossi; Patrice Céballos; Zhao-Yang Lu
Journal:  Cancer Commun (Lond)       Date:  2019-06-14

9.  Double-filtered leukoreduction as a method for risk reduction of transfusion-associated graft-versus-host disease.

Authors:  Sejong Chun; Minh-Trang Thi Phan; Saetbyul Hong; Jehoon Yang; Yeup Yoon; Sangbin Han; Jungwon Kang; Mark H Yazer; Jaehyun Kim; Duck Cho
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.